A multicenter, randomized, blinded, phase III study of pasireotide LAR versus octreotide LAR in patients with metastatic neuroendocrine tumors (NET) with disease-related symptoms inadequately controlled by somatostatin analogs.
Edward M. Wolin
Consultant or Advisory Role - Ipsen; Novartis; Pfizer
Research Funding - Ipsen; Novartis; Pfizer
Barbara Jarzab
Consultant or Advisory Role - AstraZeneca
Barbro Eriksson
Consultant or Advisory Role - Ipsen; Keocyt; Novartis; Pfizer
Thomas Walter
No relevant relationships to disclose
Christos Toumpanakis
Research Funding - Ipsen; Novartis
Other Remuneration - Ipsen; Novartis
Michael Morse
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Novartis
Paola Tomassetti
No relevant relationships to disclose
Matthias Weber
Honoraria - Novartis
Research Funding - Novartis
David R. Fogelman
No relevant relationships to disclose
John Ramage
Research Funding - Novartis
Donald Poon
No relevant relationships to disclose
Jerry M. Huang
Employment or Leadership Position - Novartis
Michelle Hudson
Employment or Leadership Position - Novartis
Xin Zhi
Employment or Leadership Position - Novartis
Janice L. Pasieka
Stock Ownership - Novartis
Abakar Mahamat
No relevant relationships to disclose
Fredrik Swahn
No relevant relationships to disclose
John Newell-Price
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Novartis
Wasat Mansoor
No relevant relationships to disclose
Kjell E. Oberg
Consultant or Advisory Role - Camurus AB; Ipsen; Novartis; Pfizer